Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iloprost
Drug ID BADD_D01135
Description Iloprost is a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).
Indications and Usage Used for the treatment of pulmonary arterial hypertension.
Marketing Status approved; investigational
ATC Code B01AC11
DrugBank ID DB01088
KEGG ID D02721
MeSH ID D016285
PubChem ID 5311181
TTD Drug ID D05ZTH
NDC Product Code 66215-303; 40016-013; 82231-109; 54893-0017; 66215-302
UNII JED5K35YGL
Synonyms Iloprost | Ciloprost | ZK-36374 | ZK 36374 | ZK36374 | Ventavis
Chemical Information
Molecular Formula C22H32O4
CAS Registry Number 78919-13-8
SMILES CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stomatitis07.05.06.005--
Stress19.06.02.0040.000164%Not Available
Subarachnoid haemorrhage17.08.01.010; 12.01.10.011; 24.07.04.0040.000082%Not Available
Sudden death08.04.01.003; 02.03.04.0130.000247%
Suffocation feeling22.12.02.0140.000123%Not Available
Supraventricular tachycardia02.03.03.012--
Swelling08.01.03.0150.000699%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.001332%
Systemic lupus erythematosus15.06.02.003; 10.04.03.004; 23.03.02.0060.000280%Not Available
Tachycardia02.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000707%Not Available
Thrombocytopenia01.08.01.002--Not Available
Trismus17.01.03.004; 15.05.04.004--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Ventricular fibrillation02.03.04.0080.000082%
Visual acuity reduced17.17.01.011; 06.02.10.0120.000123%
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Yellow skin23.03.03.042; 09.01.01.009; 08.01.03.0460.000082%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.000123%Not Available
Intracardiac thrombus02.11.01.017; 24.01.05.0030.000082%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.000716%Not Available
General physical health deterioration08.01.03.0180.002508%Not Available
Intervertebral disc protrusion15.10.01.0040.000082%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000164%Not Available
Exercise tolerance decreased08.01.03.0360.000206%Not Available
Respiratory tract congestion22.02.07.0030.000222%Not Available
Lymphatic disorder01.09.01.003--Not Available
Nasal discomfort22.12.03.0120.000123%Not Available
Organ failure08.01.03.0410.000164%Not Available
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages